By Fineline Cube 
Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that it has entered into an exclusive license agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to collaborate on the global development and commercialization of SIM0660, a CD79a/CD19/CD3 trispecific antibody with therapeutic potential for various B-cell related diseases.
Deal Structure & Key Terms
| Item | Details |
|---|---|
| Licensor | Simcere Zaiming (under Simcere Pharmaceutical, HKG: 2096) |
| Licensee | Roche |
| Asset | SIM0660 – CD79a/CD19/CD3 trispecific antibody |
| Deal Type | Exclusive global license – development, manufacturing, commercialization |
| Upfront Payment | USD 75 million |
| Total Potential Value | Up to USD 1.53 billion, upfront included |
| Royalties | Tiered, up to double-digit rates on future net sales |
| Announcement Date | 01 Sep 2026 |
Under the terms of the agreement, Roche will obtain exclusive rights to develop, manufacture, and commercialize SIM0660 worldwide. Simcere Zaiming will be eligible to receive up to USD 1.53 billion in total transaction payments, including a USD 75 million upfront payment, and may also be entitled to tiered royalties of up to double digits based on future net sales.
Drug Profile & Mechanism of Action
- Molecule: SIM0660, a trispecific T-cell engager (TCE) antibody
- Targets: CD3 (T-cell engaging arm) fused with binding domains targeting two B-cell antigens, CD79a and CD19
- Platform: Built on Simcere Zaiming‘s proprietary T-cell engager (TCE) multispecific antibody technology platform
- Mechanism: Redirects T cells to B cells via dual CD79a/CD19 engagement to drive targeted cell killing
- Differentiation: Effectively limits cytokine release while inducing potent T-cell mediated cytotoxic effects
- Potential Scope: Therapeutic potential across various B-cell related diseases
Market Impact & Outlook
- Deal scale: Total potential consideration of up to USD 1.53 billion underscores strong global appetite for next-generation T-cell engager assets from Chinese biotech
- Strategic validation: An exclusive worldwide partnership with Roche validates Simcere Zaiming‘s TCE multispecific antibody platform
- Competitive positioning: Dual B-cell targeting of CD79a and CD19 combined with a cytokine-release-limiting profile differentiates SIM0660 in the crowded immuno-oncology landscape
- Simcere upside: The USD 75 million upfront plus milestone and royalty payments create a multi-year revenue stream tied to the clinical and commercial progress of SIM0660
- Sector signal: The transaction adds momentum to the wave of cross-border oncology licensing deals between Chinese innovative drug companies and global pharmaceutical leaders
Forward‑Looking Statements – This brief contains forward-looking statements regarding the development, milestones, and commercialization of SIM0660. Actual results may differ materially due to clinical, regulatory, and market risks. This content is for informational purposes only and does not constitute investment advice.-Fineline Info & Tech